| Foreword by Andrew Fire | page xi | ||
| Foreword by Marshall Nirenberg | xiii | ||
| List of Contributors | xv | ||
| Introduction | 1 | ||
| Krishnarao Appasani | |||
| Section one. Basic RNAi, siRNA, microRNAs and gene-silencing mechanisms | |||
| 1 | RNAi beginnings. Overview of the pathway in C. elegans | 17 | |
| Alla Grishok | |||
| 2 | Dicer in RNAi: Its roles in vivo and utility in vitro | 29 | |
| Jason W. Myers and James E. Ferrell, Jr. | |||
| 3 | Genes required for RNA interference | 55 | |
| Nathaniel R. Dudley, Ahmad Z. Amin, and Bob Goldstein | |||
| 4 | MicroRNAs: A small contribution from worms | 69 | |
| Amy E. Pasquinelli | |||
| 5 | miRNAs in the brain and the application of RNAi to neurons | 84 | |
| Anna M. Krichevsky, Shih-Chu Kao, Li-Huei Tsai, and Kenneth S. Kosik | |||
| Section two. Design, synthesis of siRNAs | |||
| 6 | Design and synthesis of small interfering RNA (siRNA) | 103 | |
| Queta Boese, William S. Marshall, and Anastasia Khvorova | |||
| 7 | Automated design and high throughput chemical synthesis of siRNA | 118 | |
| Yerramilli V. B. K. Subrahmanyam and Eric Lader | |||
| 8 | Rational design of siRNAs with the Sfold software | 129 | |
| Ye Ding and Charles E. Lawrence | |||
| 9 | Enzymatic production of small interfering RNAs | 139 | |
| Muhammad Sohail and Graeme Doran | |||
| Section three. Vector development and in vivo, in vitro and in ovo delivery methods | |||
| 10 | Six methods of inducing RNAi in mammalian cells | 147 | |
| Kathy Latham, Vince Pallotta, Lance Ford, Mike Byrom, Mehdi Banan, Po-Tsan Ku, and David Brown | |||
| 11 | Viral delivery of shRNA | 161 | |
| Ying Mao, Chris Mello, Laurence Lamarcq, Brad Scherer, Thomas Quinn, Patty Wong, and Andrew Farmer | |||
| 12 | siRNA delivery by lentiviral vectors: Design and applications | 174 | |
| Oded Singer, Gustavo Tiscornia, and Inder Verma | |||
| 13 | Liposomal delivery of siRNAs in mice | 186 | |
| Mouldy Sioud and Dag R. Sørensen | |||
| 14 | Chemical modifications to achieve increased stability and sensitive detection of siRNA | 194 | |
| Philipp Hadwiger and Hans-Peter Vornlocher | |||
| 15 | RNA interference in postimplantation mouse embryos | 207 | |
| Frank Buchholz, Federico Calegari, Ralf Kittler, and Wieland B. Huttner | |||
| 16 | In ovo RNAi opens new possibilities for functional genomics in vertebrates | 220 | |
| Dimitris Bourikas, Thomas Baeriswyl, Rejina Sadhu, and Esther T. Stoeckli | |||
| Section four. Gene silencing in model organisms | |||
| 17 | Practical applications of RNAi in C. elegans | 235 | |
| Karen E. Stephens, Olivier Zugasti, Nigel J. O'Neil, and Patricia E. Kuwabara | |||
| 18 | Inducible RNAi as a forward genetic tool in Trypanosoma brucei | 247 | |
| Mark E. Drew, Shawn A. Motyka, James C. Morris, Zefeng Wang, and Paul T. Englund | |||
| 19 | RNA-mediated gene silencing in fission yeast | 257 | |
| Greg M. Arndt | |||
| 20 | RNA silencing in filamentous fungi: Mucor ciccinelloidesas a model organism | 270 | |
| Rosa M. Ruiz-Vázque | |||
| 21 | RNAi and gene silencing phenomena mediated by viral suppressors in plants | 280 | |
| Ramachandran Vanitharani, Padmanabhan Chellappan, and Claude M. Fauquet | |||
| Section five. Drug target validation | |||
| 22 | Delivering siRNA in vivo for functional genomics and novel therapeutics | 303 | |
| Patrick Y. Lu and Martin C. Woodle | |||
| 23 | The role of RNA interference in drug target validation: Application to Hepatitis C | 318 | |
| Antje Ostareck-Lederer, Sandra Clauder-Münster, Rolf Thermann, Maria Polycarpou-Schwarz, Marc Gentzel, Matthias Wilm, and Joe D. Lewis | |||
| 24 | RNAi in the drug discovery process | 331 | |
| Steven A. Haney, Peter Lapan, Jeff Aalfs, Chris Childs, Paul Yaworsky, and Chris Miller | |||
| 25 | RNA interference technology in the discovery and validation of druggable targets | 347 | |
| Neil J. Clarke, John E. Bisi, Caretha L. Creasy, Michael K. Dush, Kris J. Fisher, John M. Johnson III, Christopher J. A. Ring, and Mark R. Edbrooke | |||
| Section six. Therapeutic and drug development | |||
| 26 | RNAi-mediated silencing of viral gene expression and replication | 363 | |
| Derek M. Dykxhoorn | |||
| 27 | RNAi in drug development: Practical considerations | 384 | |
| Dmitry Samarsky, Margaret Taylor, Mark A. Kay, and Anton P. McCaffrey | |||
| 28 | RNA interference studies in liver failure | 396 | |
| Lars Zender, Michael P. Manns, and Stefan Kubicka | |||
| 29 | RNAi applications in living animal systems | 406 | |
| Lisa Scherer and John J. Rossi | |||
| Section seven. High-throughput genome-wide RNAi analysis | |||
| 30 | High-throughput RNAi by soaking in Caenorhabtis elegans | 419 | |
| Asako Sugimoto | |||
| 31 | Tools for integrative genomics: Genome-wide RNAi and expression profiling in Drosophila | 433 | |
| Michael Boutros and Marc Hild | |||
| 32 | Microarray analysis and RNA silencing to determine genes functionally important in mesothelioma | 447 | |
| Maria E. Ramos-Nino and Brooke T. Mossman | |||
| 33 | High-throughput RNA interference | 470 | |
| Howard Y. Chang, Nancy N. Wang, and Jen-Tsan Chi | |||
| 34 | Generation of highly specific vector-based shRNAi libraries directed against the entire human genome | 480 | |
| Makoto Miyagishi, Sahohime Matsumoto, Takashi Futami, Hideo Akashi, Krishnarao Appasani, Yasuomi Takagi, Shizuyo Sutou, Takashi Kadowaki, Ryozo Nagai, and Kazunari Taira | |||
| Index | 497 | ||